BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
cell-cell adhesion
,
Pseudomonas infection
,
Lung
,
Avian flu virus
,
Doxorubicin
,
PBX1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PARP 2
Summary
General Info
Curated Studies
Most Correlated Studies
Prostate adenocarcinoma LNCaP and C4-2B cells treated with PARP inhibitor Olaparib
Prostate cancer LNCaP cells treated with PARP inhibitors and with PARP1/PARP2 siRNA knockdown
Expression Analysis Upon PARP-1 or PARG Knockdown in MCF-7 Cells
PARP-1 KO and wild type T cells following CD3 and CD3/CD28 activation
Lymphoblastoid B cells treated with olaparib to inhibit poly(ADP-ribose) polymerase (PARP)
Explore Curated Studies Results
Literature
Most Relevant Literature
Studying the Immunomodulatory Functions of PARP1 and PARP2 in Mouse Models of Cancer.
Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.
Deficiency of PARP-1 and PARP-2 in the mouse uterus results in decidualization failure and pregnancy…
Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response…
Differential regulation of breast cancer bone metastasis by PARP1 and PARP2.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associate…
PD1 and PARP for Maintenance Therapy in NSLLC
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable …
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ